Dolutegravir (DTG) has been integral in the fight against HIV due to its high potency and wide accessibility. However, rising resistance rates pose a critical threat to its continued effectiveness, especially in low- and middle-income countries. This Q&A with Dr. Obiageli Okafor offers insights into the complex factors driving dolutegravir resistance and highlights potential solutions to safeguard HIV treatment programs worldwide.
As dolutegravir becomes increasingly central to both first-line antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), it’s essential for clinical labs to stay ahead of emerging resistance patterns. Dr. Okafor examines the key drivers of resistance, including gaps in viral load testing and the challenges of identifying mutations early enough to adjust treatment protocols. Additionally, the Q&A explores cutting-edge testing methods, such as next-generation sequencing (NGS), and their potential to improve detection and monitoring efforts.
Download the full Q&A to:
Understand the rising concern of dolutegravir resistance and its impact on global HIV treatment
Learn about the latest advancements in resistance testing, including the differences between Sanger sequencing and next-generation sequencing (NGS)
Explore solutions to the challenges of implementing HIV drug resistance testing in low-resource settings
Gain insights on strategies to improve global collaboration and standardize HIVDR testing and treatment approaches
